Compass Therapeutics’ (CMPX) “Buy” Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...
kalkinemedia6h
Can Maze Therapeutics Transform Genetic Medicine?
Highlights,Maze Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicines for renal, ...
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) to a strong-buy rating in a report released ...
manilatimes23h
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
Jasper expects to report data around mid-year 2025 from 4 cohorts: the 240mg single dose cohort (4 additional patients), ...
Compass Therapeutics reports Q4 EPS (11c), consensus (9c)
In 2024, we established a strong foundation for what we expect will be a transformational year ahead for Compass,” said Thomas Schuetz, MD, ...
Compass Therapeutics sees cash runway into 1Q27
As of December 31, 2024, cash and marketable securities were $127 million as compared to $152 million as of December 31, 2023, providing the ...
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the ...